Cell Therapy Drug Product Development: Technical Considerations and Challenges

被引:4
|
作者
Weng, Lindong [1 ]
机构
[1] Novo Nordisk Res Ctr Seattle Inc, Seattle, WA 98109 USA
关键词
Cryopreservation; Controlled-rate freezer; Cryoprotectant; Formulation; Fill and finish; Stability; Dose preparation; CAR T; CRYOPRESERVATION;
D O I
10.1016/j.xphs.2023.08.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cell therapy uses living cells as a drug to treat diseases. To develop a cell therapy drug product (DP), cryopreservation plays a central role in extending the shelf life of these living medicines by pausing their biological activities, especially preventing degradation, at a temperature as low as liquid nitrogen. This helps overcome the temporal and geographical gaps between centralized manufacturing and clinical administration, as well as allowing sufficient time for full release testing and flexibility in scheduling patients for administration. Cryopreservation determines or influences several key manufacturing, logistical, or clinical in-use processes, including formulation, filling, controlled rate freezing, cryogenic storage and transportation, thawing, and dose preparation. This article overviews the key technical aspects of cell therapy DP development and elucidates fundamental principles of cryobiology that should be considered when we design and optimize the relevant processes. This article also discusses the challenges that motivate continued innovation for cell therapy drug product development.(c) 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2615 / 2620
页数:6
相关论文
共 50 条
  • [31] Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations
    Kunos, Charles A.
    Galanis, Evanthia
    Buchsbaum, Jeffrey
    Shi, Qian
    Strauss, Lewis C.
    Coleman, C. Norman
    Ahmed, Mansoor M.
    JOURNAL OF NEURO-ONCOLOGY, 2017, 134 (03) : 551 - 557
  • [32] Cell cultures in drug development: Applications, challenges and limitations
    Ghanemi, Abdelaziz
    SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (04) : 453 - 454
  • [33] Future Challenges for Drug Development in Renal Cell Carcinoma
    Rini, Brian I.
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 577 - +
  • [34] Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations
    Charles A. Kunos
    Evanthia Galanis
    Jeffrey Buchsbaum
    Qian Shi
    Lewis C. Strauss
    C. Norman Coleman
    Mansoor M. Ahmed
    Journal of Neuro-Oncology, 2017, 134 : 551 - 557
  • [35] Product Quality Considerations for Mammalian Cell Culture Process Development and Manufacturing
    Gramer, Michael J.
    MAMMALIAN CELL CULTURES FOR BIOLOGICS MANUFACTURING, 2014, 139 : 123 - 166
  • [36] Challenges and opportunities in bioanalytical support for gene therapy medicinal product development
    Ma, Mark
    Balasubramanian, Nanda
    Dodge, Robert
    Zhang, Yan
    BIOANALYSIS, 2017, 9 (18) : 1423 - 1430
  • [37] Proteomic Biomarkers for Brain Disorders: Technical Considerations and Challenges
    Linda S Brady
    William Z Potter
    Neuropsychopharmacology, 2014, 39 : 252 - 252
  • [38] Proteomic Biomarkers for Brain Disorders: Technical Considerations and Challenges
    Brady, Linda S.
    Potter, William Z.
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 (01) : 252 - 252
  • [39] Drug Therapy Considerations in Circumcision
    Regen, Rebecca
    Whitehill, Jordan
    US PHARMACIST, 2012, 37 (03)
  • [40] Considerations for drug therapy in hypertension
    McNally, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2001, 55 (01) : 32 - 40